Milestone Scientific Inc. (MLSS)
| Market Cap | 28.89M -65.9% |
| Revenue (ttm) | 8.90M +3.4% |
| Net Income | -4.57M |
| EPS | -0.06 |
| Shares Out | 88.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 294,042 |
| Open | 0.3350 |
| Previous Close | 0.3355 |
| Day's Range | 0.3218 - 0.3448 |
| 52-Week Range | 0.2200 - 1.0500 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 1.00 (+206.09%) |
| Earnings Date | May 13, 2026 |
About MLSS
Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments. The company provides The Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names. It also offers CompuFlo, a computer-controlled drug delivery sys... [Read more]
Financial Performance
In 2025, Milestone Scientific's revenue was $8.97 million, an increase of 3.99% compared to the previous year's $8.63 million. Losses were -$5.72 million, 21.4% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for MLSS stock is "Buy" and the 12-month stock price target is $1.0.
News
Milestone Scientific Earnings Call Transcript: Q1 2026
Revenue and gross profit remained stable, with significant cost reductions narrowing net loss by 58%. Medical segment revenue more than doubled, driven by CompuFlo adoption and digital marketing, while new financing supports growth and international expansion.
Milestone Scientific reports Q1 EPS (1c), consensus (1c)
Reports Q1 revenue $2.16M, consensus $2.5M. “Our first quarter results reflect continued progress as we execute on the foundation established in 2025,” said Eric Hines, CEO of Milestone Scientific (ML...
Milestone Scientific backs FY26 revenue view $9.8M-$10.2M, consensus $9.91M
The company said, “Management reaffirms its outlook for the year ending December 31, 2026, with expected revenue of $9.8 million to $10.2 million, representing double-digit growth driven by expanding ...
Milestone Scientific Reports Financial Results for First Quarter 2026
Operating Loss Reduced As Company Advances Toward Profitability Reaffirms Outlook for Double-Digit Revenue Growth in 2026, including Significant Growth in CompuFlo® Sales ROSELAND, N.J., May 14, 2026 ...
Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call
ROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision...
Milestone Scientific Expands CompuFlo® Medical Business with Advisor Program and Growing National Clinical Adoption
ROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments, today provided an update on the expansion of its...
Milestone Scientific Inc. Completes $2.15 Million Private Placement
Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board Financing Strengthens Balance Sheet and Supports Comm...
Milestone Scientific Earnings Call Transcript: Q4 2025
Disciplined restructuring and targeted growth initiatives led to improved operating results in 2025, with double-digit revenue growth and significant CompuFlo expansion expected in 2026. Cash flow break even is targeted for early 2027.
Milestone Scientific reports Q4 revenue $2.1M, consensus $2.31M
Eric Hines, CEO of Milestone Scientific (MLSS) commented: “When I joined Milestone in August 2025, we were in the middle of the third quarter following a period without consistent executive…
Milestone Scientific sees FY26 revenue $9.8M-$10.2M, consensus $9.91M
The company said, “As we enter 2026, we expect to transition from a period of stabilization to a more offensive posture, investing selectively in initiatives that accelerate growth while maintaining…
Milestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025
Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March ...
Milestone Scientific Schedules Fourth Quarter and FY 2025 Financial Results and Business Update Conference Call
ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precisi...
Milestone Scientific launches CompuFlo Advisor Program
Milestone Scientific (MLSS) announced the launch of the CompuFlo Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, ...
Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precisio...
Milestone Scientific launches The Wand Ambassador Program
Milestone Scientific (MLSS) announced the launch of The Wand Ambassador Program, a scalable peer-to-peer engagement initiative designed to expand clinical awareness, education, and adoption of The Wan...
Milestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry
Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months Pilot launched with six registered dental professionals; program expected to scale ...
Milestone Scientific price target lowered to $1 from $1.25 at Benchmark
Benchmark lowered the firm’s price target on Milestone Scientific (MLSS) to $1 from $1.25 and keeps a Speculative Buy rating on the shares. Sales traction for the Medical business has…
Milestone Scientific Earnings Call Transcript: Q3 2025
Q3 2025 saw stable revenue and gross profit, with operating expenses reduced by $500,000 year-over-year. Dental remains the main revenue driver, while medical segment efforts focus on targeted Medicare reimbursement and commercial rollout. Cash position supports operations for several quarters.
Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025
ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, to...
Milestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference Call
ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, to...
Milestone Scientific highlights growth initiatives unser new CEO Eric Hines
Milestone Scientific (MLSS) provided a business update highlighting the Company’s transformation and growth initiatives under the leadership of its new CEO Eric Hines. Since joining Milestone Scientif...
Milestone Scientific receives non-compliance notification from NYSE American
Milestone Scientific (MLSS) received a letter from NYSE American dated October 8, stating that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii)…
Milestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership
Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone Scientific for accelerated growth and i...
Milestone Scientific Commits to Regaining NYSE American Compliance Following Notification
Notification has no immediate effect on the Company's listing or day-to-day operations Notification has no immediate effect on the Company's listing or day-to-day operations
Milestone Scientific appoints Dawood Sayed to board of directors
Milestone Scientific (MLSS) announced the appointment of Dawood Sayed to its Board of Directors, effective immediately. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Ka...